Open Access
International Journal of Inflammation
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q3
WOS
Q3
Impact factor
2.6
SJR
0.465
CiteScore
3.8
Categories
Immunology and Allergy
Areas
Medicine
Years of issue
2012-2024
journal names
International Journal of Inflammation
INT J INFLAMM
Top-3 citing journals

International Journal of Molecular Sciences
(225 citations)

Frontiers in Immunology
(165 citations)

Scientific Reports
(121 citations)
Top-3 organizations

Cornell University
(6 publications)

Harvard University
(6 publications)

Imperial College London
(5 publications)

Airlangga university
(2 publications)

Hamedan University of Medical Sciences
(2 publications)

IPB University
(2 publications)
Top-3 countries
Most cited in 5 years
Found
Publications found: 3647
Q3

Comparative In Silico and In Vitro Studies of Novel Zinc/Tin Metal Coordinates Bearing BRCA-1 Mimetics on Wtp53 and Mtp53 Proteins
Negi P., Swaroop A.K., Singh A.K., Saranya R., Esakkimuthukumar M., Raj P.V., Jawahar N., Jubie S.
Purpose:
This study compares the activity of BRCA-1 mimetics on WTp53 (wild-type
p53 protein) and MTp53 (mutated-type p53 protein) proteins, examining the impact of TP53
mutations in breast cancer. p53 activators can be a new insight and synthesis of effective
compounds for the treatment of cancer. The project contributes to the growing body of research on
p53 activators and provides new insights into the design and synthesis of effective compounds for
the treatment of cancer.
Methods:
Molecular docking predicted binding affinity values for WTp53 and MTp53. The MMGBSA
of top compounds was run to get binding-free energies. The MD simulations were
calculated, and six metal coordinates were synthesized. In vitro MTT-assays were performed with
WTp53 (MCF-7) and R273H-MTp53 (MDA-MB-468) cell lines, comparing results with known
p53 activator PRIMA-1 (p53-reactivation and induction of massive apoptosis-1).
Results:
The p53 activators established a three-featured (2RA, 1HBA) pharmacophore. The
designed compounds had better Glide gscore compared to p53 activators PRIMA-1, PRIMA-1-
MET (methylated PRIMA-1), and Tamoxifen with p53 protein (WTp53, R175H and R273H
MTp53). The MM-GBSA results of top compounds showed binding free energies with R175HMTp53
(-22.24 to -75.45 kcal/mol), R273H-MTp53 (-22.8 to -36.36 kcal/mol), and WTp53 (-26.45
to -50.3 kcal/mol) compared to the p53 activator. The MD simulation of TSCO5/3KMD-MT in 100
ns indicated a stable complex when compared to TSCO5/3KMD-WT. The six metal coordinates
(TSCO5-Zn, TSCO6-Zn, TSCO6-Sn, TSCO13-Zn, TSCO13-Sn, TSCO9-Sn) were synthesised.
Based on in vitro results, IC50 for TSCO5-Zn (WTp53: 0.089μM, MTp53: 0.074μM) and TSCO5-
Sn (WTp53: 0.092μM, MTp53: 0.073μM) have shown significant cytotoxicity.
Conclusion:
As compared to PRIMA-1, the designed compound TSCO5 metal coordinates have
shown good in silico and in vitro activity on mutated p53 cell lines and are more potent than the
p53 activator PRIMA-1.
Q3

miR-584-5p Regulates MSMO1 to Modulate the AKT/PI3K Pathway and Inhibit Breast Cancer Progression
Li X., Liu J., He L., Tian M., Xu Y., Peng B.
Introduction:
Endogenous microRNAs (miRNAs) are critical regulators of tumor progression,
making their role in breast cancer an important area of investigation.
Method:
This study examined the regulation of MSMO1 by miR-584-5p in breast cancer cells. Using
bioinformatics and Western blotting, we confirmed MSMO1 expression in breast cancer cells
and evaluated its effects on cell migration, invasion, and the AKT signaling pathway. In vivo experiments
further supported these findings. The interaction between miR-584-5p and MSMO1
was validated through luciferase reporter assays, while functional studies highlighted the impact
of miR-584-5p on cancer progression.
objective:
study sought to elucidate the molecular underpinnings of miR-584-5p-mediated regulation of MSMO1 in breast cancer
Result:
Our findings revealed that MSMO1 is upregulated in breast cancer, enhancing cell migration
and invasion. Silencing MSMO1 diminished AKT pathway activity, and luciferase assays confirmed
MSMO1 as a direct target of miR-584-5p.
Conclusion:
Overexpression of miR-584-5p suppressed migration and invasion of breast cancer
cells. In summary, miR-584-5p is likely to modulate MSMO1 and subsequently regulate the AKT/
PI3K pathway, presenting a promising therapeutic target for breast cancer treatment.
Q3

A Review on the Potential Role of Humanin Peptide and its Analogs in the Regulation of Autophagy Pathways for Therapeutic Application in Metabolic Disorders
Moin H., Ashraf R., Butt B., Mustafa I., Shafiq M., Shah S.A.
Autophagy is a self-eating cellular process in which the cell breaks down worn-out organelles,
damaged/defective proteins, and toxins. Impaired autophagy is a significant factor in the
development of various metabolic disorders, along with oxidative stress, inflammation, mitochondrial
and endoplasmic reticulum dysfunction. These disorders pose a significant health and economic
burden on the global human population, owing to their steadily rising prevalence. Therefore,
modulating the expression of proteins involved in the autophagy-related pathways can be a
promising avenue for curbing the development and progression of these disorders. Humanin (HN)
is a 24-amino acid mitochondrial-derived peptide. It possesses anti-oxidant, anti-inflammatory,
and pro-apoptotic properties. The analogs of HN can be generated by replacing specific amino
acids in the polypeptide chain, thereby functionally modifying the peptide. Among these, humanin-
glycine (HNG) is the most widely studied analog in both in vivo and in vitro disease models. It
is far more potent than HN, with a potency that is 1000 times greater. To the best of our knowledge,
this review is the first to discuss and examine the available evidence regarding the potential
involvement of HN or its analogs in regulating autophagy pathways. The review primarily highlights
that HN is an autophagy inducer, which can promote cell survival in the presence of
metabolic and oxidative stress, particularly the HNG analog. Future research is imperative to comprehensively
evaluate the effects of HN and its analogs on autophagy. Further investigations are
needed to correlate its levels with various autophagic markers in different metabolic diseases, offering
the potential for groundbreaking discoveries in understanding disease mechanisms and developing
novel therapeutic strategies.
Q3

Inconsistent Protein Stability Despite Pre-HECT Domain Helix: Unveiling Variability in HECT Ligases
Dağ Ç., Tozkoparan Ceylan C.D., Cansız C.S.
Introduction:
Ubiquitin and ubiquitin-like systems play crucial roles across a wide
range of organisms, from simple to complex. Among the three enzyme-mediated post-translational
modification (PTM) steps, the ligation step is the most critical. HERC5, a member of the HECT
ligase family, is one of the three enzymes involved in the ISGylation system. However, the precise
start points and lengths of the HECT domains in HECT ligases are still under debate.
Method:
Some studies suggest the inclusion of an additional N-terminal alpha helix region within
the HECT domain. To investigate the structural biology of the HECT domain of HERC5, we produced
and purified various lengths of the HERC5 HECT domain using different fusion proteins.
This approach allowed us to explore the role of the N-terminal alpha helix in the stability of the
HECT domain. Our experiments successfully produced and purified HERC5 HECT domains of
different lengths with various fusion proteins.
Result:
The findings demonstrated that the N-terminal alpha-helix does not enhance the stability
of the HECT domain. These results challenge the notion that the N-terminal alpha-helix should be
generally included in the HECT domain across all HECT ligases.
Conclusion:
The inclusion of this region within the HECT domain may not be appropriate for generalization,
as it does not contribute to stability, contrary to some previous suggestions.
conclusion:
These results challenge the notion that the N-terminal alpha helix should be generally included in the HECT domain across all HECT ligases. The inclusion of this region within the HECT domain may not be appropriate for generalization, as it does not contribute to stability, contrary to some previous suggestions.
Q3

Anti-Cancer Bioactive Peptide Induces Apoptosis in Gastric Cancer Cells through TP53 Signaling Cascade
Suyila Q., Li X., Su X.
Introduction:
Gastric cancer has emerged as one of the major diseases threatening human
health. Our previous studies indicated that the anti-cancer bioactive peptide (ACBP) inhibits
the initiation and progression of gastric cancer through apoptosis and cell cycle arrest, yet the
mechanisms remain unclear. To elucidate the relationships between the effects of ACBP and the
levels of cell differentiation, as well as the functional mechanisms of ACBP, we conducted a
study using three human gastric cancer cell lines: NCI-N87, MGC-803, and another unspecified
line.
Method:
We investigated the impact of ACBP on the survival and morphology of these cancer
cell lines, examined apoptosis and cell cycle progression, and detected the expression of TP53,
TP63, and TP73 in cancer cells, as well as the expression of Bax, PUMA, and Mcl-1 in a xenograft
mouse model. ACBP inhibited the proliferation of all three cancer cell lines in a dose-dependent
manner, similar to the positive control and 5-fluorouracil (5-FU). The effect of ACBP correlated
with the degree of differentiation of the cancer cells; the lower the differentiation degree, the
stronger the inhibitory effect.
Result:
After ACBP treatment, the expression of TP53, TP63, and TP73 increased in all cell lines.
In the xenograft mouse model, ACBP inhibited the growth of MGC-803 cells in vivo. The apoptotic-
related genes Bax and PUMA were upregulated, while Mcl-1 was downregulated. ACBP inhibited
tumor cell growth by inducing apoptosis through the TP53 signaling cascade, upregulating
TP53, TP63, and TP73 and their downstream apoptosis-promoting genes Bax and PUMA while
downregulating the anti-apoptotic gene Mcl-1.
Conclusion:
Notably, after ACBP treatment, Mcl-1 expression was significantly reduced in the tumor
tissue of the xenograft model, indicating that ACBP induced apoptosis through the TP53 signaling
cascade. This project provides a scientific basis for exploring the antitumor mechanism of
ACBP in gastric cancer therapy.
other:
This project provides a scientific basis for exploring the antitumor mechanism of ACBP in gastric cancer therapy.
Q3

iRGD Tumor Penetrating Peptide-Modified NK Cells Exhibit Enhanced Tumor Immune Infiltration Ability and Anti-Tumor Efficacy
Song G., Qi X., Zhao Y.
Background:
Natural killer (NK) cells, as part of the group I innate lymphocytes (ILCs)
are essential for tumor immune surveillance. NK cells can recognize and eliminate target cells
without the need for prior sensitization or restriction of major histocompatibility complexes
(MHCs) and antigens. However, the limited infiltration of metastatic NK cells poses significant
challenges for advancing adoptive cell immunotherapy for solid tumors.
Objective:
This study aimed to explore the potential of using tumor penetrating peptide (TPP)
iRGD to promote the delivery of activated NK cells to deeper layers of tumor tissue.
Methods:
Flow cytometry was performed to evaluate the activation, inhibition, and expression of
other receptors involved in cytotoxicity. High-pressure liquid chromatography (HPLC) and mass
spectrometry were used to detect the purity of iRGD. 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-poly(ethylene glycol)-iRGD (DSPE-PEG-iRGD) was synthesized. Surface
modification of cells was performed using DSPE-PEG-iRGD. Multicellular tumor spheroids
(MCTSs) were established to evaluate permeability. In addition, in order to better simulate the
physiological characteristics of solid tumors in vivo, we generated 3D spheroids from HGC27
gastric cancer cell line and BXPC-3 pancreatic cancer cell line to study the anti-tumor effect of NK
cells with combination iRGD in vitro. The mouse models of gastric cancer and pancreatic cancer
were used. In addition, the synergistic anti-tumor effects were evaluated in vivo based on the tumor
volume and body weight of mice.
Results:
Initially, we treated NK cells with interleukin-2 (IL-2), resulting in significant activation
as indicated by upregulation of CD56. On the 15th day, the proliferation of CD3-/56+cell
population in NK cell culture containing IL-2 significantly increased, and the NK cell amplification
factor was greater than 300. In addition, NK cells exhibited increased cytotoxicity towards cancer
cell lines. When the ratio of effect to target was 10:1, the killing rate of NK cells against BXPC-3
was 83.1%. iRGD modification enabled NK cells to penetrate MCTSs, resulting in cytotoxicity
against target HGC27 and BXPC-3 cells. In addition, NK cells modified with iRGD significantly
reduced tumor growth in the xenotransplantation model of gastric cancer and pancreatic cancer
mice model.
Conclusion:
In summary, our results indicated that NK cells exhibited higher efficacy and lifespan
against cancer cell lines in vitro. Furthermore, the integration of iRGD into NK cells led to
improved infiltration and targeted elimination of MCTSs. Moreover, the application of iRGDmodified
NK cells has shown significant anti-tumor efficacy against solid tumors in vivo. This joint
strategy may significantly improve the efficacy of NK cell immunotherapy in treating various solid
tumors.
Q3

Clay-Polymer Nanocomposites Mediated Inhibition of Protein Aggregation: Possible Role in the Prevention of Proteinopathies
Parveen R., Ali S., Fatima S.
Background:
The transformation of proteins from their native conformation into highly
ordered fibrillar structures due to their misfolding and aggregation under particular conditions are
described as beta-sheet enriched amyloid fibrils. The accumulation of these fibrils in different
body parts is the major cause of several neurological and non-neurological conditions (proteinopathies).
Objectives:
To prevent these proteinopathies, inhibition of protein aggregation is considered a
promising strategy. Therefore, in this study, we synthesized montmorillonite (MMT) based poly-
orthophenylenediamine (PoPD) nanocomposites (NCs) and characterized their size and morphology
due to their remarkable biological properties. Further, the effect of these nanocomposites
on inhibition of fibril formation was assessed.
Methods:
These nanocomposites were evaluated for their anti-amyloidogenic potential on two
model proteins of amyloidopathies, i.e., human lysozyme and human serum albumin (HL &
HSA), by using several biophysical methods, such as Thioflavin T (ThT) and 1-anilino-8-naphthalene
sulfonate (ANS) fluorescence, congo red dye binding assay (CR). Secondary structural content
was evaluated by Circular dichroism (CD) spectroscopy.
Results:
Results demonstrated that synthesized nanocomposites significantly inhibited fibril formation
in dose-dependent manner that corresponds to their ability to arrest fibrillation. It is suggested
that they may adsorb proteins to protect them against aggregation when they are subjected to aggregating
conditions.
Conclusion:
This study offers an opportunity to understand the mechanism of inhibition of fibril
formation by nanocomposites, showing that they inhibit amyloid formation and amyloid diseases.
Thus, the study concludes that these nanocomposites are promising candidates as therapeutic
molecules for proteinopathies and are envisaged to enrich the area of personalized medicine, augmenting
the human healthcare system.
Q3

Structural and Functional Insights into UDGs
Roy S., Azhar M.K., Gupta V.
Abstract:
Endogenous or exogenous DNA damage needs to be repaired, therefore, cells in all the
three domains have repair pathways to maintain the integrity of their genetic material. Uracil
DNA glycosylases (UDGs), also known as UNGs (uracil-DNA N-glycosylases), are part of the
base-excision repair (BER) pathway. These enzymes specifically remove uracil from DNA
molecules by cleaving the glycosidic bond between the uracil base and the deoxyribose sugar.
UDGs can be broadly classified into six families, and each of them share conserved motifs that are
critical for substrate recognition and catalysis. Recently, an unconventional UDG known as
UDGX has been identified from the species Mycobacterium smegmatis, which is different from
other UDG members in forming an irreversible and extremely stable complex with DNA that is resistant
to even harsh denaturants such as SDS, NaOH, and heat. This suicide inactivation mechanism
prevents uracil excision and might play a protective role in maintaining genome integrity,
as bacterial survival under hypoxic conditions is reduced due to the overexpression of MsmUDGX.
Additionally, due to the importance of UDGs, the number of structures has been resolved.
Moreover, high-resolution 3D structures of apo MsmUDGX, as well as uracil and DNAbound
forms, are available in PDB. This review aims to provide insights into the specific structural-
functional aspects of each UDG family member for theragnostic applications.
Q3

Pro-fertility and Antioxidant Potentials of Vigna unguiculata (Cowpea) Protein Isolate and Essential Oil: An In vivo and In silico Studies
Samuel Oladimeji O., Kayode Awote O., Olympian Elum N.
Introduction::
Vigna unguiculata (Cowpea), a legume rich in phytochemicals, has been
traditionally used to improve fertility and treat various ailments. This study used in-silico and invivo
methods to evaluate the effects of cowpea protein isolate and essential oil on reproductive hormonal
and antioxidant indices.
Method::
Forty (40) female rats were divided into eight groups (n=5). After 14 days of treatment,
hormone levels (progesterone, prolactin, testosterone and estradiol) and antioxidant activities (superoxide
dismutase (SOD), catalase (CAT) were assessed using biochemical kits and standard procedures.
Molecular docking studies were performed using PyRx and Biovia Discovery Studio
2021. The ligands generated through gas chromatography-mass spectroscopy (GCMS) analysis of
cowpea oil and the target proteins (SOD and CAT) were from downloaded PubChem and RCSB
Protein Data Bank, respectively.
Results::
The results of this study showed that cowpea essential oil and protein isolate significantly
(p<0.05) reduced plasma CAT and SOD activities while increasing their activities in the ovary
and liver tissues compared to the infertile untreated group. Consistent administration of either cowpea
oil or protein isolate was observed to positively regulate the hormonal indices in the infertile
treated groups. Phthalic acid, 2-cyclohexyl ethyl isobutyl ester demonstrated a strong binding
affinity and binding constant with SOD and CAT, which suggests that the ligands from cowpea essential
oil may have antioxidant and pro-fertility properties that could be developed to treat fertility-
related issues.
Conclusion::
Based on the results of this study, it can be concluded that V. unguiculata has antioxidant
property, and can promote fertility, possibly through its rich embedded phytochemicals,
which substantiates its traditional claim.
Q3

Amphibian-Derived Antimicrobial Peptides: Essential Components of Innate Immunity and Potential Leads for New Antibiotic Development
O E.T.
Abstract:
Like other vertebrates, amphibians possess innate and adaptive immune systems. At the
center of the adaptive immune system is the Major Histocompatibility Complex. The important
molecules of innate immunity are antimicrobial peptides (AMPs). These peptides are secreted by
granular glands in the skin and protect the animal against microorganisms entering its body
through the skin. AMPs offer an effective and rapid defense against pathogenic microorganisms
and have cationic and amphiphilic structures. These peptides are small gene-encoded molecules of
8-50 amino acid residues synthesized by ribosomes. These small molecules typically exhibit activity
against bacteria, viruses, fungi, and even cancer cells. It is known that today's amphibian AMPs
originated from a common precursor gene 150 million years ago and that the origin of these peptides
is preprodermaseptins. Today, antibiotic resistance has occurred due to the incorrect use of
antibiotics. Traditional antibiotics are becoming increasingly inadequate. AMPs are considered
promising candidates for the development of new-generation antibiotics. Therefore, new antibiotic
discoveries are needed. AMPs are suitable molecules for new-generation antibiotics that are both
fast and have different killing mechanisms. One of the biggest problems in the clinical applications
of AMPs is their poor stability. AMPs generally have limited tropical applications because
they are sensitive to protease degradation. Coating these peptides with nanomaterials to make
them more stable can solve this problem.
Q3

ZP3 Expression in Pancreatic Adenocarcinoma: Its Implications for the Prognosis and Therapy
Lyu G., Li D.
Background:
The role of Zona pellucida glycoprotein 3 (ZP3) is unclear in pancreatic
adenocarcinoma (PAAD).
Objective:
This study aimed to explore the role of ZP3 in PAAD.
Methods:
A comparative analysis of ZP3 gene expression was performed to discern differences between
various types of cancer and PAAD, leveraging data sourced from The Cancer Genome Atlas
(TCGA). This study aimed to assess the role of ZP3 as a potential diagnostic marker for
PAAD. The relationship between ZP3 levels and clinical characteristics, as well as patient outcomes,
was scrutinized. Additionally, genomic enrichment analysis was carried out to uncover the
underlying regulatory mechanisms associated with ZP3. The study further delved into the association
of ZP3 with immune system interactions, checkpoint gene expression, Tumor Mutational Burden
(TMB), microsatellite instability (MSI), and tumor stemness index (mRNAsi). The aberrant
expression patterns of ZP3 in PAAD cell cultures were confirmed through the application of quantitative
reverse transcription PCR (qRT-PCR) techniques.
Results:
ZP3 exhibited aberrant expression in both pan-cancer and PAAD. A significant correlation
was observed between increased levels of ZP3 expression in PAAD patients and histologic
grade (p = 0.026). Elevated ZP3 expression in PAAD was found to be significantly associated
with poorer overall survival (p = 0.003), progression-free survival (p = 0.012), and disease-specific
survival (p = 0.002). In PAAD, the level of ZP3 gene expression was statistically significant (p
< 0.001) and recognized as a key determinant of patient prognosis. ZP3 exhibited associations
with various biological pathways, including primary immunodeficiency, oxidative phosphorylation,
and other pathways. ZP3 expression demonstrated correlations with immune infiltration, immune
checkpoint genes, TMB, MSI, and mRNAsi in PAAD. Moreover, a pronounced negative
correlation was detected between ZP3 expression levels and the therapeutic effectiveness of various
medications, including selumetinib, bleomycin, FH535, docetaxel, and tanespimycin, within
the context of PAAD. Elevated levels of ZP3 were consistently observed in cell line models of
PAAD.
Conclusion:
ZP3 has the potential to serve as a prognostic biomarker and therapeutic target for patients
with PAAD.
Q3

Molecular Interactions of the Antimicrobial Peptide Tritrpticin with Mixed Nanoaggregates: A Fluorescence Spectroscopy Study
Rocha K.C., Brasil M.C., Cilli E.M., Salay L.C.
Introduction:
Tritrpticin (TRP3) is a peptide belonging to the cathelicidin family and
has a broad spectrum of antimicrobial activity. However, this class of biomolecules can be easily
degraded in the body, making it necessary to use an efficient transport system. The ability to form
stable nanostructures from the interaction of glycyrrhizin saponin with the pluronic polymer F127
was demonstrated, forming mixed biopolymeric micelles, highly promising as drug carriers.
Objective:
The present work sought to understand the physicochemical interaction of the antimicrobial
peptide TRP3 with the mixed polymeric micelle made from pluronic F127 and the saponin
glycyrrhizin.
Methods:
The interaction of tritrpticin with mixed nanostructured micelles was evaluated through
fluorescence spectroscopy and fluorescence quenching with acrylamide. The experiments were
performed at room temperature (25 ± 1°C), adopting an excitation wavelength set to 280 nm and
emission between 300 and 500 nm, with a slit of 5 nm.
Results:
The interaction of the cationic peptide tritrpticin with the mixed biopolymeric micelles
was observed through the blue shift of the fluorescence emission to shorter wavelengths, proving
the change of tryptophan to a more hydrophobic environment. Through the fluorescence suppression
technique, it was possible to indicate the location of the peptide in the mixed micelles, proving
tritrpticin to be partially inserted inside them.
Conclusion:
It was concluded that tritrpticin interacted with mixed nanostructured micelles, forming
a promising system for biotechnological applications.
Q3

ZNF165: A Pan-Cancer Biomarker with Prognostic and Therapeutic Potential
Lyu G., Li D.
Background:
The role of ZNF165 in only a few tumors has been reported. ZNF165
plays an important role in liver cancer, gastric cancer, and breast cancer, especially in regulating
the immune microenvironment, promoting tumor cell proliferation and migration, and serving as a
potential target for immunotherapy.
Objective:
This study aimed to enhance an understanding of how the ZNF165 gene functions and
influences cancer development.
Methods:
Using a suite of online resources, including TIMER, TCGA, GTEx, GEPIA2, cBioPortal,
TIMER2, STRING, DAVID, RNAactDrug, CancerSEA, and UCSC, along with comprehensive
statistical analyses, we conducted a thorough investigation of the pan-cancer landscape of ZNF165.
This study encompassed an assessment of ZNF165 levels, their associations with patient outcomes,
and clinical correlates. We examined the interplay between ZNF165 and key cancer biomarkers,
such as Microsatellite Instability (MSI), Tumor Mutational Burden (TMB), immune cell
infiltration, and the expression of immune checkpoint genes. We delved into the genetic variations
of ZNF165, its biological roles across various cancer types, and its potential links to drug responsiveness.
We analyzed single-cell expression patterns of ZNF165 and their implications for the
functional dynamics of cancer. We employed quantitative Reverse Transcription PCR (qRT-PCR)
to measure ZNF165 levels in Ovarian Cancer (OC) cell lines.
Results:
ZNF165 expression displayed aberrations across a diverse range of human cancers and
exhibited correlations with clinical stages. High ZNF165 expression in KIRC, KIRP, STAD, and
UCEC was significantly associated with poor overall survival. ZNF165 has encouraging diagnostic
value in specific tumor types, with gene amplification identified as the predominant genetic alteration.
Our analysis further uncovered significant associations between ZNF165 levels and MSI
across three distinct cancer types, as well as with TMB in six different malignancies. We detected
substantial correlations between ZNF165 levels and immune cell infiltration, as well as the expression
of immune checkpoint genes. ZNF165 was found to be involved in several prevalent signaling
pathways across various cancer types. ZNF165 may potentially contribute to chemotherapy
and chemoresistance, and was observed to be involved in cancer progression. A ceRNA regulatory
network involving AFDN-DT, miR-191-5p, and ZNF165 was constructed for OC, revealing significantly
elevated ZNF165 levels in OC cell lines. Dysregulated ZNF165 expression across a
spectrum of malignancies might play a role in cancer initiation and advancement via multiple biological
pathways.
Conclusion:
ZNF165 may serve as a promising therapeutic target for the treatment of cancer in human
patients.
Q3

MARVELD1 Promotes the Invasiveness in Pancreatic Adenocarcinoma through the Activation of Epithelial-to-Mesenchymal Transition
Luo X., Gao Z.
Background:
MARVEL domain-containing 1 (MARVELD1) has been implicated in
the progression of several cancers, but its role in pancreatic adenocarcinoma (PAAD) remains
poorly understood.
background:
Pancreatic adenocarcinoma (PAAD) is a highly malignant form of cancer that originates in the pancreas, with its exocrine cells producing digestive enzymes. MARVEL domain-containing 1 (MARVELD1) is a protein that plays a significant role in various cellular processes.
Methods:
RNA-seq data from the TCGA-PAAD and GTEx-Pancreas cohorts were analyzed to assess
MARVELD1 expression. Stable MARVELD1 knockdown and overexpression were conducted
in BxPC3 and PANC-1 cells. Cell viability, proliferation, migration, and invasion were evaluated
using functional assays, and western blotting was employed to examine EMT-associated protein
levels, including Vimentin, MMP2, MMP9, and E-cadherin. Differentially expressed genes
(DEGs) between MARVELD1-high and MARVELD1-low groups were identified, and pathway
enrichment analyses were performed.
Results::
We observed a significant increase of MARVELD1 in PAAD patient samples, with elevated
MARVELD1 levels correlating with poor clinical survival. Knockdown of MARVELD1 in
PAAD cells remarkably decreased cell proliferation and colony formation, while overexpression
of MARVELD1 enhanced these properties. Moreover, simulated cell invasion and migration assay
further suggested that MARVELD1 might contribute to PAAD cell aggressiveness. Mechanistically,
MARVELD1 promoted tumor cell migration and invasion through the activation of Vimentin,
MMP2, and MMP9 protein while suppressing E-cadherin. Bioinformatics analysis revealed
that MARVELD1-high samples were enriched in EMT-related pathways, including TGF-β
receptor signaling, actin cytoskeleton regulation, and cell adhesion.
Conclusion::
Taken together, our study highlights the roles of MARVELD1 in promoting tumor
cell proliferation and invasion, suggesting its potential application as a prognostic and diagnostic
biomarker for PAAD in the clinical context.
conclusion:
Taken together, our study highlights that MARVELD1 is a tumor-promoting gene and might be a prognostic factor and potential therapeutic target for PAAD in clinical.
Top-100
Citing journals
50
100
150
200
250
|
|
International Journal of Molecular Sciences
225 citations, 2.95%
|
|
Frontiers in Immunology
165 citations, 2.16%
|
|
Scientific Reports
121 citations, 1.58%
|
|
PLoS ONE
114 citations, 1.49%
|
|
AIP Conference Proceedings
98 citations, 1.28%
|
|
Frontiers in Pharmacology
65 citations, 0.85%
|
|
Cells
56 citations, 0.73%
|
|
Journal of Clinical Medicine
42 citations, 0.55%
|
|
Molecules
40 citations, 0.52%
|
|
Nutrients
37 citations, 0.48%
|
|
Frontiers in Cardiovascular Medicine
36 citations, 0.47%
|
|
Biomedicines
30 citations, 0.39%
|
|
BioMed Research International
28 citations, 0.37%
|
|
World Journal of Gastroenterology
28 citations, 0.37%
|
|
International Journal of Biological Macromolecules
28 citations, 0.37%
|
|
Cureus
28 citations, 0.37%
|
|
Pharmaceutics
27 citations, 0.35%
|
|
Life Sciences
24 citations, 0.31%
|
|
Oxidative Medicine and Cellular Longevity
24 citations, 0.31%
|
|
Frontiers in Physiology
24 citations, 0.31%
|
|
Frontiers in Cell and Developmental Biology
22 citations, 0.29%
|
|
Frontiers in Microbiology
22 citations, 0.29%
|
|
Clinical Rheumatology
21 citations, 0.27%
|
|
Mediators of Inflammation
21 citations, 0.27%
|
|
Evidence-based Complementary and Alternative Medicine
21 citations, 0.27%
|
|
Ocular Immunology and Inflammation
20 citations, 0.26%
|
|
Biomedicine and Pharmacotherapy
20 citations, 0.26%
|
|
Journal of Immunology
19 citations, 0.25%
|
|
Journal of Ethnopharmacology
19 citations, 0.25%
|
|
Biomolecules
19 citations, 0.25%
|
|
Journal of Immunology Research
18 citations, 0.24%
|
|
International Immunopharmacology
18 citations, 0.24%
|
|
Journal of Neuroinflammation
18 citations, 0.24%
|
|
Inflammatory Bowel Diseases
18 citations, 0.24%
|
|
F1000Research
18 citations, 0.24%
|
|
Experimental and Therapeutic Medicine
18 citations, 0.24%
|
|
Molecular Medicine Reports
17 citations, 0.22%
|
|
Experimental Eye Research
17 citations, 0.22%
|
|
Antioxidants
17 citations, 0.22%
|
|
Arteriosclerosis, Thrombosis, and Vascular Biology
16 citations, 0.21%
|
|
Graefe's Archive for Clinical and Experimental Ophthalmology
15 citations, 0.2%
|
|
International Journal of Molecular Medicine
15 citations, 0.2%
|
|
Medicine (United States)
15 citations, 0.2%
|
|
Cancers
15 citations, 0.2%
|
|
Inflammopharmacology
14 citations, 0.18%
|
|
Frontiers in Bioengineering and Biotechnology
14 citations, 0.18%
|
|
Frontiers in Medicine
14 citations, 0.18%
|
|
Pharmaceuticals
13 citations, 0.17%
|
|
Retina
13 citations, 0.17%
|
|
Cytokine
13 citations, 0.17%
|
|
Circulation Research
13 citations, 0.17%
|
|
Frontiers in Oncology
13 citations, 0.17%
|
|
American Journal of Physiology - Gastrointestinal and Liver Physiology
13 citations, 0.17%
|
|
Expert Review of Clinical Immunology
12 citations, 0.16%
|
|
Cellular and Molecular Life Sciences
12 citations, 0.16%
|
|
Journal of Molecular and Cellular Cardiology
12 citations, 0.16%
|
|
Food and Function
12 citations, 0.16%
|
|
Frontiers in Endocrinology
12 citations, 0.16%
|
|
Heliyon
12 citations, 0.16%
|
|
Rheumatology International
12 citations, 0.16%
|
|
Nature Communications
11 citations, 0.14%
|
|
Journal of the American Heart Association
11 citations, 0.14%
|
|
Microorganisms
11 citations, 0.14%
|
|
Medical Hypotheses
11 citations, 0.14%
|
|
Autoimmunity Reviews
11 citations, 0.14%
|
|
International Journal of Inflammation
11 citations, 0.14%
|
|
Journal of Drug Delivery Science and Technology
11 citations, 0.14%
|
|
Inflammation
11 citations, 0.14%
|
|
Journal of Ophthalmology
10 citations, 0.13%
|
|
FASEB Journal
10 citations, 0.13%
|
|
Journal of Functional Foods
10 citations, 0.13%
|
|
Applied Sciences (Switzerland)
10 citations, 0.13%
|
|
Journal of Translational Medicine
10 citations, 0.13%
|
|
Annals of Biomedical Engineering
10 citations, 0.13%
|
|
Frontiers in Cellular and Infection Microbiology
10 citations, 0.13%
|
|
American Journal of Physiology - Heart and Circulatory Physiology
10 citations, 0.13%
|
|
Life
10 citations, 0.13%
|
|
Molecular Neurobiology
10 citations, 0.13%
|
|
International Journal of Environmental Research and Public Health
9 citations, 0.12%
|
|
Journal of Crohn's and Colitis
9 citations, 0.12%
|
|
Biochemical and Biophysical Research Communications
9 citations, 0.12%
|
|
Journal of wound care
9 citations, 0.12%
|
|
Rheumatology
9 citations, 0.12%
|
|
Pancreatology
9 citations, 0.12%
|
|
Journal of Clinical Investigation
8 citations, 0.1%
|
|
Viruses
8 citations, 0.1%
|
|
Molecular Biology Reports
8 citations, 0.1%
|
|
PeerJ
8 citations, 0.1%
|
|
Arthritis Research and Therapy
8 citations, 0.1%
|
|
Journal of Cellular Physiology
8 citations, 0.1%
|
|
Oncotarget
8 citations, 0.1%
|
|
Genes
8 citations, 0.1%
|
|
Progress in Retinal and Eye Research
8 citations, 0.1%
|
|
Polymers
8 citations, 0.1%
|
|
Molecular and Cellular Biochemistry
8 citations, 0.1%
|
|
Atherosclerosis
8 citations, 0.1%
|
|
Current Pharmaceutical Design
8 citations, 0.1%
|
|
Journal of Cellular and Molecular Medicine
8 citations, 0.1%
|
|
Frontiers in Neuroscience
8 citations, 0.1%
|
|
Advances in Experimental Medicine and Biology
8 citations, 0.1%
|
|
Show all (70 more) | |
50
100
150
200
250
|
Citing publishers
200
400
600
800
1000
1200
1400
1600
|
|
Elsevier
1457 citations, 19.07%
|
|
Springer Nature
1181 citations, 15.46%
|
|
MDPI
806 citations, 10.55%
|
|
Wiley
651 citations, 8.52%
|
|
Frontiers Media S.A.
515 citations, 6.74%
|
|
Taylor & Francis
312 citations, 4.08%
|
|
Hindawi Limited
261 citations, 3.42%
|
|
Ovid Technologies (Wolters Kluwer Health)
195 citations, 2.55%
|
|
Oxford University Press
134 citations, 1.75%
|
|
Public Library of Science (PLoS)
133 citations, 1.74%
|
|
AIP Publishing
111 citations, 1.45%
|
|
SAGE
109 citations, 1.43%
|
|
American Chemical Society (ACS)
86 citations, 1.13%
|
|
Cold Spring Harbor Laboratory
79 citations, 1.03%
|
|
Spandidos Publications
74 citations, 0.97%
|
|
Mary Ann Liebert
65 citations, 0.85%
|
|
American Physiological Society
60 citations, 0.79%
|
|
Baishideng Publishing Group
58 citations, 0.76%
|
|
Royal Society of Chemistry (RSC)
51 citations, 0.67%
|
|
Bentham Science Publishers Ltd.
50 citations, 0.65%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
39 citations, 0.51%
|
|
BMJ
33 citations, 0.43%
|
|
S. Karger AG
32 citations, 0.42%
|
|
American Society for Microbiology
26 citations, 0.34%
|
|
IntechOpen
21 citations, 0.27%
|
|
The American Association of Immunologists
20 citations, 0.26%
|
|
F1000 Research
18 citations, 0.24%
|
|
Walter de Gruyter
17 citations, 0.22%
|
|
American Society for Clinical Investigation
16 citations, 0.21%
|
|
IOP Publishing
16 citations, 0.21%
|
|
Pleiades Publishing
15 citations, 0.2%
|
|
Cambridge University Press
14 citations, 0.18%
|
|
Media Sphere Publishing House
14 citations, 0.18%
|
|
Impact Journals
13 citations, 0.17%
|
|
Federation of American Societies for Experimental Biology (FASEB)
13 citations, 0.17%
|
|
The Company of Biologists
12 citations, 0.16%
|
|
King Saud University
11 citations, 0.14%
|
|
AME Publishing Company
11 citations, 0.14%
|
|
Mark Allen Group
11 citations, 0.14%
|
|
Georg Thieme Verlag KG
10 citations, 0.13%
|
|
Portland Press
10 citations, 0.13%
|
|
Association for Research in Vision and Ophthalmology (ARVO)
10 citations, 0.13%
|
|
Oriental Scientific Publishing Company
10 citations, 0.13%
|
|
A and V Publications
10 citations, 0.13%
|
|
Research Square Platform LLC
10 citations, 0.13%
|
|
PeerJ
9 citations, 0.12%
|
|
American Thoracic Society
9 citations, 0.12%
|
|
Proceedings of the National Academy of Sciences (PNAS)
8 citations, 0.1%
|
|
Hans Publishers
8 citations, 0.1%
|
|
Rockefeller University Press
7 citations, 0.09%
|
|
Pharmaceutical Society of Japan
7 citations, 0.09%
|
|
7 citations, 0.09%
|
|
Medknow
7 citations, 0.09%
|
|
Mediar Press
7 citations, 0.09%
|
|
XMLink
7 citations, 0.09%
|
|
IOS Press
6 citations, 0.08%
|
|
eLife Sciences Publications
6 citations, 0.08%
|
|
Annual Reviews
6 citations, 0.08%
|
|
Maad Rayan Publishing Company
6 citations, 0.08%
|
|
Academic Journals
5 citations, 0.07%
|
|
Bioscientifica
5 citations, 0.07%
|
|
4 citations, 0.05%
|
|
American Scientific Publishers
4 citations, 0.05%
|
|
American Society for Pharmacology and Experimental Therapeutics
4 citations, 0.05%
|
|
Society of Nuclear Medicine
4 citations, 0.05%
|
|
Eco-Vector LLC
4 citations, 0.05%
|
|
Editorial Office of Gut and Liver
4 citations, 0.05%
|
|
4 citations, 0.05%
|
|
Society for Neuroscience
4 citations, 0.05%
|
|
Japan Atherosclerosis Society
4 citations, 0.05%
|
|
Canadian Science Publishing
4 citations, 0.05%
|
|
Japanese Society of Internal Medicine
4 citations, 0.05%
|
|
IGI Global
4 citations, 0.05%
|
|
Scientific Scholar
4 citations, 0.05%
|
|
European Molecular Biology Organization
4 citations, 0.05%
|
|
EDP Sciences
3 citations, 0.04%
|
|
American Association for the Advancement of Science (AAAS)
3 citations, 0.04%
|
|
Higher Education Press
3 citations, 0.04%
|
|
Microbiology Society
3 citations, 0.04%
|
|
Korean Society of Neurogastroenterology and Motility
3 citations, 0.04%
|
|
The Egyptian Society for Joint Diseases and Arthritis
3 citations, 0.04%
|
|
American Medical Association (AMA)
3 citations, 0.04%
|
|
Laser Application in Medical Sciences Research Center
3 citations, 0.04%
|
|
Veterinary World
3 citations, 0.04%
|
|
European Respiratory Society (ERS)
3 citations, 0.04%
|
|
SPb RAACI
3 citations, 0.04%
|
|
ASME International
3 citations, 0.04%
|
|
Korean College of Rheumatology
3 citations, 0.04%
|
|
The Japanese Circulation Society
3 citations, 0.04%
|
|
IMA Press, LLC
3 citations, 0.04%
|
|
Remedium, Ltd.
3 citations, 0.04%
|
|
Jaypee Brothers Medical Publishing
3 citations, 0.04%
|
|
Arterialnaya Gipertenziya
3 citations, 0.04%
|
|
Medical Informational Agency Publishers
3 citations, 0.04%
|
|
Brieflands
3 citations, 0.04%
|
|
SLACK
3 citations, 0.04%
|
|
The Journal of Rheumatology
3 citations, 0.04%
|
|
World Scientific
2 citations, 0.03%
|
|
American Diabetes Association
2 citations, 0.03%
|
|
The Royal Society
2 citations, 0.03%
|
|
Show all (70 more) | |
200
400
600
800
1000
1200
1400
1600
|
Publishing organizations
1
2
3
4
5
6
|
|
Cornell University
6 publications, 2.13%
|
|
Harvard University
6 publications, 2.13%
|
|
Imperial College London
5 publications, 1.77%
|
|
University of the West Indies at Cave Hill, Barbados
4 publications, 1.42%
|
|
University of Tokyo
4 publications, 1.42%
|
|
Helsinki University Hospital
3 publications, 1.06%
|
|
University of Naples Federico II
3 publications, 1.06%
|
|
University of Oslo
3 publications, 1.06%
|
|
Sorbonne University
3 publications, 1.06%
|
|
University of Otago
3 publications, 1.06%
|
|
Washington University in St. Louis
3 publications, 1.06%
|
|
Duke University Hospital
3 publications, 1.06%
|
|
Brigham and Women's Hospital
3 publications, 1.06%
|
|
University of California, Los Angeles
3 publications, 1.06%
|
|
McGill University
3 publications, 1.06%
|
|
King Abdulaziz University
2 publications, 0.71%
|
|
Tehran University of Medical Sciences
2 publications, 0.71%
|
|
Banaras Hindu University
2 publications, 0.71%
|
|
Hamedan University of Medical Sciences
2 publications, 0.71%
|
|
L. V. Prasad Eye Institute
2 publications, 0.71%
|
|
Technical University of Munich
2 publications, 0.71%
|
|
Uppsala University
2 publications, 0.71%
|
|
Tampere University Hospital
2 publications, 0.71%
|
|
University Hospital of Zürich
2 publications, 0.71%
|
|
Chongqing Medical University
2 publications, 0.71%
|
|
American University of Beirut
2 publications, 0.71%
|
|
Queen Mary University of London
2 publications, 0.71%
|
|
University of Oxford
2 publications, 0.71%
|
|
Oslo University Hospital
2 publications, 0.71%
|
|
University of Manchester
2 publications, 0.71%
|
|
University of Birmingham
2 publications, 0.71%
|
|
Yale University
2 publications, 0.71%
|
|
University of Basilicata
2 publications, 0.71%
|
|
Columbia University
2 publications, 0.71%
|
|
Tokyo Medical and Dental University
2 publications, 0.71%
|
|
Airlangga university
2 publications, 0.71%
|
|
IPB University
2 publications, 0.71%
|
|
Clemson University
2 publications, 0.71%
|
|
West Virginia University
2 publications, 0.71%
|
|
Case Western Reserve University
2 publications, 0.71%
|
|
Massachusetts General Hospital
2 publications, 0.71%
|
|
Kyoto University
2 publications, 0.71%
|
|
University of Szeged
2 publications, 0.71%
|
|
Kwame Nkrumah University of Science and Technology
2 publications, 0.71%
|
|
National and Kapodistrian University of Athens
2 publications, 0.71%
|
|
Academy of Athens
2 publications, 0.71%
|
|
Paris Cité University
2 publications, 0.71%
|
|
University of Michigan
2 publications, 0.71%
|
|
Université de Sherbrooke
2 publications, 0.71%
|
|
University of British Columbia
2 publications, 0.71%
|
|
University Medical Center Utrecht
2 publications, 0.71%
|
|
University of Regensburg
2 publications, 0.71%
|
|
Jagiellonian University
2 publications, 0.71%
|
|
University of Texas MD Anderson Cancer Center
2 publications, 0.71%
|
|
Universidade Estadual Paulista
2 publications, 0.71%
|
|
Erasmus University Medical Center
2 publications, 0.71%
|
|
University of Pennsylvania
2 publications, 0.71%
|
|
University of Toronto
2 publications, 0.71%
|
|
University of Calgary
2 publications, 0.71%
|
|
University of Miami
2 publications, 0.71%
|
|
University of Rochester Medical Center
2 publications, 0.71%
|
|
Cleveland Clinic Lerner College of Medicine
2 publications, 0.71%
|
|
University of Colorado Anschutz Medical Campus
2 publications, 0.71%
|
|
University of Tennessee Health Science Center
2 publications, 0.71%
|
|
A.P. Avtsyn Research Institute of Human Morphology
1 publication, 0.35%
|
|
South Ural State Medical University
1 publication, 0.35%
|
|
National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia
1 publication, 0.35%
|
|
Federal State Budget Institution «A.N. Bakulev National Medical Research Center of Cardiovascular Surgery»
1 publication, 0.35%
|
|
Russian-Armenian University
1 publication, 0.35%
|
|
Institute of Molecular Biology National Academy of Sciences of the Republic of Armenia
1 publication, 0.35%
|
|
Imam Mohammad Ibn Saud Islamic University
1 publication, 0.35%
|
|
Hacettepe University
1 publication, 0.35%
|
|
Koc University
1 publication, 0.35%
|
|
Mashhad University of Medical Sciences
1 publication, 0.35%
|
|
Tabriz University of Medical Sciences
1 publication, 0.35%
|
|
United Arab Emirates University
1 publication, 0.35%
|
|
Bahcesehir University
1 publication, 0.35%
|
|
Isfahan University of Medical Sciences
1 publication, 0.35%
|
|
All India Institute of Medical Sciences, Delhi
1 publication, 0.35%
|
|
Imam Abdulrahman Bin Faisal University
1 publication, 0.35%
|
|
Erciyes University
1 publication, 0.35%
|
|
JSS Academy of Higher Education & Research
1 publication, 0.35%
|
|
Saveetha Institute of Medical and Technical Sciences
1 publication, 0.35%
|
|
University of Technology, Iraq
1 publication, 0.35%
|
|
University of Sulaimani
1 publication, 0.35%
|
|
Qazvin University of Medical Sciences
1 publication, 0.35%
|
|
Mazandaran University of Medical Sciences
1 publication, 0.35%
|
|
Shariati Hospital
1 publication, 0.35%
|
|
University of Basrah
1 publication, 0.35%
|
|
Başkent University
1 publication, 0.35%
|
|
Yozgat Bozok University
1 publication, 0.35%
|
|
Hawler Medical University
1 publication, 0.35%
|
|
University of Misan
1 publication, 0.35%
|
|
Tata Institute of Fundamental Research
1 publication, 0.35%
|
|
SRM Institute of Science and Technology
1 publication, 0.35%
|
|
National Institute for Research in Reproductive and Child Health
1 publication, 0.35%
|
|
Bu-Ali Sina University
1 publication, 0.35%
|
|
Dezful University of Medical Sciences
1 publication, 0.35%
|
|
Shahid Sadoughi University of Medical Sciences
1 publication, 0.35%
|
|
Dr. Babasaheb Ambedkar Marathwada University
1 publication, 0.35%
|
|
Show all (70 more) | |
1
2
3
4
5
6
|
Publishing organizations in 5 years
1
2
|
|
Hamedan University of Medical Sciences
2 publications, 3.7%
|
|
Airlangga university
2 publications, 3.7%
|
|
IPB University
2 publications, 3.7%
|
|
Universidade Estadual Paulista
2 publications, 3.7%
|
|
South Ural State Medical University
1 publication, 1.85%
|
|
National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia
1 publication, 1.85%
|
|
King Abdulaziz University
1 publication, 1.85%
|
|
Koc University
1 publication, 1.85%
|
|
Tabriz University of Medical Sciences
1 publication, 1.85%
|
|
Bahcesehir University
1 publication, 1.85%
|
|
Isfahan University of Medical Sciences
1 publication, 1.85%
|
|
Imam Abdulrahman Bin Faisal University
1 publication, 1.85%
|
|
University of Technology, Iraq
1 publication, 1.85%
|
|
Qazvin University of Medical Sciences
1 publication, 1.85%
|
|
University of Basrah
1 publication, 1.85%
|
|
Başkent University
1 publication, 1.85%
|
|
University of Misan
1 publication, 1.85%
|
|
Bu-Ali Sina University
1 publication, 1.85%
|
|
Dezful University of Medical Sciences
1 publication, 1.85%
|
|
Shahid Sadoughi University of Medical Sciences
1 publication, 1.85%
|
|
Sina Hospital
1 publication, 1.85%
|
|
Jordan University of Science and Technology
1 publication, 1.85%
|
|
Chongqing Medical University
1 publication, 1.85%
|
|
Hebei Medical University
1 publication, 1.85%
|
|
American University of Beirut
1 publication, 1.85%
|
|
National Institute for Materials Science
1 publication, 1.85%
|
|
Sorbonne University
1 publication, 1.85%
|
|
Drexel University
1 publication, 1.85%
|
|
Yale University
1 publication, 1.85%
|
|
University of Queensland
1 publication, 1.85%
|
|
Translational Research Institute
1 publication, 1.85%
|
|
Princess Alexandra Hospital (Australia)
1 publication, 1.85%
|
|
Stellenbosch University
1 publication, 1.85%
|
|
Columbia University
1 publication, 1.85%
|
|
University of Limpopo
1 publication, 1.85%
|
|
Diponegoro University
1 publication, 1.85%
|
|
Mulawarman University
1 publication, 1.85%
|
|
Covenant University
1 publication, 1.85%
|
|
Kyung Hee University
1 publication, 1.85%
|
|
Clemson University
1 publication, 1.85%
|
|
University of California, Los Angeles
1 publication, 1.85%
|
|
Dong-A University
1 publication, 1.85%
|
|
University of California, Davis
1 publication, 1.85%
|
|
Kwame Nkrumah University of Science and Technology
1 publication, 1.85%
|
|
University of Cape Coast
1 publication, 1.85%
|
|
National Autonomous University of Mexico
1 publication, 1.85%
|
|
Université Paris-Est Créteil
1 publication, 1.85%
|
|
University of Texas MD Anderson Cancer Center
1 publication, 1.85%
|
|
Wrocław University of Environmental and Life Sciences
1 publication, 1.85%
|
|
University of Toronto
1 publication, 1.85%
|
|
Louisiana State University Health Sciences Center Shreveport
1 publication, 1.85%
|
|
Al-Azhar University
1 publication, 1.85%
|
|
Paris Sciences et Lettres
1 publication, 1.85%
|
|
Beni-Suef University
1 publication, 1.85%
|
|
Damanhour University
1 publication, 1.85%
|
|
Sunnybrook Health Sciences Centre
1 publication, 1.85%
|
|
Show all (26 more) | |
1
2
|
Publishing countries
10
20
30
40
50
60
70
80
90
|
|
USA
|
USA, 81, 28.72%
USA
81 publications, 28.72%
|
United Kingdom
|
United Kingdom, 25, 8.87%
United Kingdom
25 publications, 8.87%
|
Japan
|
Japan, 23, 8.16%
Japan
23 publications, 8.16%
|
Brazil
|
Brazil, 20, 7.09%
Brazil
20 publications, 7.09%
|
India
|
India, 18, 6.38%
India
18 publications, 6.38%
|
Germany
|
Germany, 13, 4.61%
Germany
13 publications, 4.61%
|
Canada
|
Canada, 12, 4.26%
Canada
12 publications, 4.26%
|
Italy
|
Italy, 11, 3.9%
Italy
11 publications, 3.9%
|
China
|
China, 10, 3.55%
China
10 publications, 3.55%
|
Indonesia
|
Indonesia, 10, 3.55%
Indonesia
10 publications, 3.55%
|
Switzerland
|
Switzerland, 10, 3.55%
Switzerland
10 publications, 3.55%
|
France
|
France, 9, 3.19%
France
9 publications, 3.19%
|
Greece
|
Greece, 8, 2.84%
Greece
8 publications, 2.84%
|
Iran
|
Iran, 7, 2.48%
Iran
7 publications, 2.48%
|
Poland
|
Poland, 7, 2.48%
Poland
7 publications, 2.48%
|
Mexico
|
Mexico, 6, 2.13%
Mexico
6 publications, 2.13%
|
Australia
|
Australia, 5, 1.77%
Australia
5 publications, 1.77%
|
New Zealand
|
New Zealand, 5, 1.77%
New Zealand
5 publications, 1.77%
|
Turkey
|
Turkey, 5, 1.77%
Turkey
5 publications, 1.77%
|
Barbados
|
Barbados, 4, 1.42%
Barbados
4 publications, 1.42%
|
Egypt
|
Egypt, 4, 1.42%
Egypt
4 publications, 1.42%
|
Spain
|
Spain, 4, 1.42%
Spain
4 publications, 1.42%
|
Netherlands
|
Netherlands, 4, 1.42%
Netherlands
4 publications, 1.42%
|
Norway
|
Norway, 4, 1.42%
Norway
4 publications, 1.42%
|
Singapore
|
Singapore, 4, 1.42%
Singapore
4 publications, 1.42%
|
Finland
|
Finland, 4, 1.42%
Finland
4 publications, 1.42%
|
Sweden
|
Sweden, 4, 1.42%
Sweden
4 publications, 1.42%
|
Russia
|
Russia, 3, 1.06%
Russia
3 publications, 1.06%
|
Denmark
|
Denmark, 3, 1.06%
Denmark
3 publications, 1.06%
|
Malaysia
|
Malaysia, 3, 1.06%
Malaysia
3 publications, 1.06%
|
Malta
|
Malta, 3, 1.06%
Malta
3 publications, 1.06%
|
Saudi Arabia
|
Saudi Arabia, 3, 1.06%
Saudi Arabia
3 publications, 1.06%
|
South Africa
|
South Africa, 3, 1.06%
South Africa
3 publications, 1.06%
|
Kazakhstan
|
Kazakhstan, 2, 0.71%
Kazakhstan
2 publications, 0.71%
|
Austria
|
Austria, 2, 0.71%
Austria
2 publications, 0.71%
|
Belgium
|
Belgium, 2, 0.71%
Belgium
2 publications, 0.71%
|
Bulgaria
|
Bulgaria, 2, 0.71%
Bulgaria
2 publications, 0.71%
|
Hungary
|
Hungary, 2, 0.71%
Hungary
2 publications, 0.71%
|
Ghana
|
Ghana, 2, 0.71%
Ghana
2 publications, 0.71%
|
Israel
|
Israel, 2, 0.71%
Israel
2 publications, 0.71%
|
Iraq
|
Iraq, 2, 0.71%
Iraq
2 publications, 0.71%
|
Ireland
|
Ireland, 2, 0.71%
Ireland
2 publications, 0.71%
|
Cameroon
|
Cameroon, 2, 0.71%
Cameroon
2 publications, 0.71%
|
Lebanon
|
Lebanon, 2, 0.71%
Lebanon
2 publications, 0.71%
|
Republic of Korea
|
Republic of Korea, 2, 0.71%
Republic of Korea
2 publications, 0.71%
|
Ukraine
|
Ukraine, 1, 0.35%
Ukraine
1 publication, 0.35%
|
Estonia
|
Estonia, 1, 0.35%
Estonia
1 publication, 0.35%
|
Portugal
|
Portugal, 1, 0.35%
Portugal
1 publication, 0.35%
|
Algeria
|
Algeria, 1, 0.35%
Algeria
1 publication, 0.35%
|
Armenia
|
Armenia, 1, 0.35%
Armenia
1 publication, 0.35%
|
Jordan
|
Jordan, 1, 0.35%
Jordan
1 publication, 0.35%
|
Kenya
|
Kenya, 1, 0.35%
Kenya
1 publication, 0.35%
|
Morocco
|
Morocco, 1, 0.35%
Morocco
1 publication, 0.35%
|
Nigeria
|
Nigeria, 1, 0.35%
Nigeria
1 publication, 0.35%
|
UAE
|
UAE, 1, 0.35%
UAE
1 publication, 0.35%
|
Pakistan
|
Pakistan, 1, 0.35%
Pakistan
1 publication, 0.35%
|
Syria
|
Syria, 1, 0.35%
Syria
1 publication, 0.35%
|
Ethiopia
|
Ethiopia, 1, 0.35%
Ethiopia
1 publication, 0.35%
|
Show all (28 more) | |
10
20
30
40
50
60
70
80
90
|
Publishing countries in 5 years
2
4
6
8
10
12
|
|
USA
|
USA, 11, 20.37%
USA
11 publications, 20.37%
|
Indonesia
|
Indonesia, 9, 16.67%
Indonesia
9 publications, 16.67%
|
Brazil
|
Brazil, 6, 11.11%
Brazil
6 publications, 11.11%
|
Poland
|
Poland, 5, 9.26%
Poland
5 publications, 9.26%
|
Iran
|
Iran, 4, 7.41%
Iran
4 publications, 7.41%
|
China
|
China, 3, 5.56%
China
3 publications, 5.56%
|
France
|
France, 2, 3.7%
France
2 publications, 3.7%
|
Kazakhstan
|
Kazakhstan, 2, 3.7%
Kazakhstan
2 publications, 3.7%
|
Egypt
|
Egypt, 2, 3.7%
Egypt
2 publications, 3.7%
|
Republic of Korea
|
Republic of Korea, 2, 3.7%
Republic of Korea
2 publications, 3.7%
|
South Africa
|
South Africa, 2, 3.7%
South Africa
2 publications, 3.7%
|
Russia
|
Russia, 1, 1.85%
Russia
1 publication, 1.85%
|
Australia
|
Australia, 1, 1.85%
Australia
1 publication, 1.85%
|
Bulgaria
|
Bulgaria, 1, 1.85%
Bulgaria
1 publication, 1.85%
|
Ghana
|
Ghana, 1, 1.85%
Ghana
1 publication, 1.85%
|
Jordan
|
Jordan, 1, 1.85%
Jordan
1 publication, 1.85%
|
Iraq
|
Iraq, 1, 1.85%
Iraq
1 publication, 1.85%
|
Cameroon
|
Cameroon, 1, 1.85%
Cameroon
1 publication, 1.85%
|
Canada
|
Canada, 1, 1.85%
Canada
1 publication, 1.85%
|
Lebanon
|
Lebanon, 1, 1.85%
Lebanon
1 publication, 1.85%
|
Mexico
|
Mexico, 1, 1.85%
Mexico
1 publication, 1.85%
|
Nigeria
|
Nigeria, 1, 1.85%
Nigeria
1 publication, 1.85%
|
Saudi Arabia
|
Saudi Arabia, 1, 1.85%
Saudi Arabia
1 publication, 1.85%
|
Turkey
|
Turkey, 1, 1.85%
Turkey
1 publication, 1.85%
|
Switzerland
|
Switzerland, 1, 1.85%
Switzerland
1 publication, 1.85%
|
Ethiopia
|
Ethiopia, 1, 1.85%
Ethiopia
1 publication, 1.85%
|
Japan
|
Japan, 1, 1.85%
Japan
1 publication, 1.85%
|
2
4
6
8
10
12
|
1 profile journal article
Tsvetkov Ivan
PhD in Biological/biomedical sciences

A.P. Avtsyn Research Institute of Human Morphology
36 publications,
198 citations
h-index: 7